Dréno, Brigitte
Ascierto, Paolo A
Atkinson, Victoria
Liszkay, Gabriella
Maio, Michele
Mandalà, Mario
Demidov, Lev
Stroyakovskiy, Daniil
Thomas, Luc
de la Cruz-Merino, Luis
Dutriaux, Caroline
Garbe, Claus
Bartley, Karen
Karagiannis, Thomas
Chang, Ilsung
Rooney, Isabelle
Koralek, Daniel O
Larkin, James
McArthur, Grant A
Ribas, Antoni
Article History
Received: 5 June 2017
Revised: 11 December 2017
Accepted: 15 December 2017
First Online: 13 February 2018
Competing interests
: BD has been a consultant or advisor for BMS, GlaxoSmithKline, Roche, and Novartis; has served on speakers’ bureaus for BMS, GlaxoSmithKline, and Roche; has received research funding from BMS and GlaxoSmithKline; and has had travel accommodations and expenses paid for by BMS and Roche. PAA has been a consultant or advisor for BMS, Roche/Genentech, MSD, Novartis, Amgen, Array, and Merck Serono; and has received research funding from BMS, Roche/Genentech, and Array. VA has received speaker fees from, has been an advisor for, and has had travel support from BMS, MSD, and Novartis. GL has been an advisor for BMS, Roche, MSD, and Novartis. MMaio has received honoraria from, has been a consultant or advisor and has served on speakers’ bureaus for, and has had travel accommodations and expenses paid for by BMS, Roche, GlaxoSmithKline, MedImmune, MSD, and AstraZeneca; and has received research funding from BMS and MedImmune. LD has been an advisor for and has received research funding from BMS, Roche, MSD, and Novartis. LdlC-M has been an advisor and served on speakers’ bureaus for and has received research funding from BMS, Roche-Farma, Novartis, and Merck-MSD. CG has received honoraria from and has been a consultant or advisor for Philogen, Amgen, BMS, GlaxoSmithKline, Merck, Novartis, and Roche; has received research funding from BMS, GlaxoSmithKline, and Roche; and has had travel accommodations and expenses paid for by Amgen, BMS, GSK, Merck, Novartis, and Roche. KB is an employee of Genentech and owns stock in Roche/Genentech. TK and IR are employees of and own stock in Genentech. IC is an employee of, owns stock in, has received honoraria from, has been a consultant or advisor for, served on speaker’s bureaus for, holds patents for, has provided expert testimony for, and has had travel accommodations and expenses paid for by Genentech. DOK is a former employee of Genentech and is currently an employee of and owns stock in Agios Pharmaceuticals. JL has been a nonrenumerated consultant for BMS, GlaxoSmithKline, Novartis, MSD, Roche/Genentech, and Pfizer. GAM has been a consultant or advisor for Provectus; has received research funding from Pfizer, Celgene, and Ventana; and has had travel accommodations and expenses paid for by Roche and Novartis. AR has been a consultant or advisor for Roche, Amgen, Pfizer, and Merck; and owns stock in Compugen, CytomX, Five Prime, and Kite Pharma. The remaining authors declare no conflict of interest.